6 results about "Azelnidipine" patented technology

The invention relates to an application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and medicinal preparations. The invention provides application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV (human papillomavirus) infection. The dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. According to the scheme, the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV is reported for the first time, and an in-vitro cell experiment is carried out through azelnidipine in the dihydropyridine compound; furthermore, the inhibition effect on the HPV virus is verified through mouse intradermal vaccination virus model drug delivery and mouse vaginal vaccination virus model drug delivery.

The application relates to application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and pharmaceutical preparations. The application provides application of the dihydropyridine compound or the salt thereof in preparation of the medicine for preventing and / or treating HPV infection, wherein the dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. The application scheme first reports the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV, and in-vitro cell experiments are carried out through azelnidipine in the dihydropyridine compound, and further, the inhibiting effect of the dihydropyridine compound on HPV virus is verified through medicine administration of a mouse intradermal virus inoculation model and medicine administration of a mouse vaginal virus inoculation model.

This invention discloses the application of the compound Azelnidipine in the preparation of antiviral drugs, relating to the field of biomedical technology. This invention successfully explores the novel application value of the compound Azelnidipine and its pharmaceutically acceptable salts in the prevention and control of African swine fever. Azelnidipine possesses excellent ability to inhibit the replication of African swine fever virus, exerting intervention effects at different stages of viral infection and exhibiting good concentration-dependent action. It also possesses high biocompatibility, causing no significant damage to host cells, thus balancing antiviral efficacy and biocompatibility. Furthermore, this compound can not only be used to prepare various dosage forms of drugs for the prevention and / or treatment of African swine fever virus infection, but can also be extended to serve as an adjuvant for African swine fever vaccines, possessing very broad prospects for industrial application and market value.

The invention discloses an application of a compound Azelnidipine in preparation of an antiviral drug, and relates to the technical field of biological medicines. The invention successfully explores a brand new application value of the compound Azelnidipine and the pharmaceutically acceptable salt thereof in the field of prevention and control of African swine fever. The Azelnidipine has excellent capability of inhibiting African swine fever virus replication, not only can play an intervention role in different stages of virus infection, but also can present good action concentration correlation, meanwhile, also has relatively high biological safety, does not cause obvious damage to host related cells, and gives consideration to both antiviral effect and biocompatibility. Besides, the compound not only can be used for preparing various dosage forms of medicines for preventing and / or treating African swine fever virus infection, but also can be expanded as an African swine fever vaccine adjuvant, and has very wide industrial application prospects and market values.

The present invention belongs to the technical field of organic synthesis, and specifically relates to a method for preparing azelnidipine with large particle size. The method comprises the following steps: step 1: adding azelnidipine crude product to a good solvent, heating to 30-40°C; step 2: cooling, adding a poor solvent, and performing the first crystallization; step 3: heating to 28-33°C, adding a poor solvent, and performing the second crystallization; step 4: cooling to 18-23°C, and performing the third crystallization; step 5: continuing to cool to 8-12°C, and performing the fourth crystallization; step 6: further cooling to 0-5°C, and performing the fifth crystallization, and separating and obtaining azelnidipine; wherein, in step 1, the good solvent is dichloromethane; in steps 2 and 3, the poor solvent is n-heptane. The D90 particle size of the azelnidipine obtained by the present invention is above 110 μm, which can realize the efficient separation of azelnidipine, reduce the production energy consumption, and the yield and purity of the obtained azelnidipine are high, which is more suitable for industrial production.

The invention belongs to the technical field of organic synthesis, and particularly relates to a preparation method of azelnidipine. The preparation method of azelnidipine comprises the following steps: step 1, adding m-nitrobenzaldehyde and isopropyl acetoacetate into a solvent for reaction, and after the reaction is finished, obtaining a reaction solution containing an intermediate or separating the reaction solution to obtain the intermediate; and step 2, adding 1-benzhydryl-3-azetidinol amidino acetate acetate, an alkaline reagent and orthoester, and continuing to react with the intermediate to obtain azelnidipine. The orthoester dehydrating agent is added to catalyze the reaction, so that the target product can be obtained by adopting a post-treatment mode of adding water to crystallize after the reaction is finished, the reaction time is shortened, the impurity content in the system is reduced, and the reaction efficiency is improved; in addition, introduction of redundant organic solvents and inorganic salts is avoided, and the risks that API solvent residues exceed the standard and firing residues are unqualified are reduced.